Metabolism and Pharmacokinetics

  • Jun Shi
  • Vijay O. Bhargava
  • Shashank Rohatagi

The role of metabolism and pharmacokinetics, under an industrial context, is to address the question of which compound should be selected for development among multiple candidates and how the compound should be dosed. As a discipline, pharmacokinetics (PK) is the study of what the body does to the drug, that is, the absorption, distribution, metabolism, and excretion (ADME) of the drug, whereas pharmacodynamics (PD) seeks to define what the drug does to the body, that is, the exposure and the response relationship. The integration of PK and PD in drug development from early to late stage can guide the decision-making process on lead generation, optimization, and product realization.


Biopharmaceutics Classification System Allometric Scaling Dose Proportionality Lead Candidate Mass Balance Study 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Rohatagi S, Barrett J. Pharmacokinetic/pharmacodynamic modeling in drug Development. In: Applications of Pharmacokinetic Principles in Drug Development, Ed. Krishna R. Kluwer Academic/ Plenum Publishers 2003Google Scholar
  2. 2.
    Rowland M, Tozer TN. Clinical Pharmacokinetics, Concepts and Application, third ed. Williams & Wilkins, Baltimore. 1995Google Scholar
  3. 3.
    Li AP, Ed. Advances in Pharmacology: Drug-Drug Interactions: Scientific and Regulatory Perspectives. San Diego, CA: Academic Press. 1997, pp. 43, 189–203Google Scholar
  4. 4.
    Bjornsson TD, Callaghan JT, Einolf HJ, Fischer V, Gan L, Grimm S, Kao J, King SP, Miwa G, Ni L, Kumar G, McLeod J, Obach SR, Roberts S, Roe A, Shah A, Snikeris F, Sullivan JT, Tweedie D, Vega JM, Walsh J, Wrighton SA. The conduct of in vitro and in vivo drug-drug interaction studies: a PhRMA perspective. J Clin Pharmacol 2003;43(5):443–469PubMedGoogle Scholar
  5. 5.
    Natarajan C, Rohatagi S. Role of Pharmacokinetics in Preclinical Development. In: Industrial Pharmacokinetics, Eds. Bonate P, Howard D. AAPS Press 2004Google Scholar
  6. 6.
    Ho RH, Kim RB. Transporters and drug therapy: implications for drug disposition and Disease. Clin Pharmacol Ther 2005;78:260–277CrossRefPubMedGoogle Scholar
  7. 7.
    Defining genetic influences on pharmacologic responses. Drug interactions table. Available at
  8. 8.
    Evans WE, Johnson JA. Pharmacogenomics: the inherited basis for inter individual differences in drug response. Ann Rev Genomics Human Genetics 2001;2:9–39CrossRefGoogle Scholar
  9. 9.
    Kalow W. Pharmacogenetics, pharmacogenomics, and pharmacobiology. Clin Pharmacol Ther 2001;70(1):1–4CrossRefPubMedGoogle Scholar
  10. 10.
    FDA Guidance. Bioanalytical method validation. U.S. FOAGoogle Scholar
  11. 11.
    Chaikin P, Rhodes GR, Rohatagi S, Natarajan C. Pharmacokinetics/pharmacodynamics in drug development: an industrial perspective. J Clin Pharmacol 2000;40:1428–1438PubMedGoogle Scholar
  12. 12.
    Guidance for Industry. Estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, July 2005Google Scholar
  13. 13.
    U.S. Food and Drug Administration (CDER). Guidance for Industry, Investigators, and Reviewers: Exploratory IND Studies (DRAFT GUIDANCE). April 2005Google Scholar
  14. 14.
    Shah B, Emmons G, Rohatagi S, Martin NE, Howell S, Jensen BK. Mass balance study of 14C–M100240, a dual ACE/NEP inhibitor in healthy male subjects. Am J Ther 2003;10:356–362CrossRefPubMedGoogle Scholar
  15. 15.
    Rohatagi S, Wang Y, Argenti D. Mass balance studies. In: Industrial Pharmacokinetics, Eds Bonate P, Howard D. AAPS Press, 2004Google Scholar
  16. 16.
    Rohatagi S, Barrett JS, DeWitt KE, Morales, RJ. Integrated pharmacokinetic/metabolic modeling of selegiline after transdermal administration. Biopharm Drug Disp 1997:18(7): 567–584CrossRefGoogle Scholar
  17. 17.
    Shi J, Montay G, Bhargava VO. Clinical pharmacokinetics of telithromycin, the first ketolide antibacterial. Clin Pharmacokinet 2005;44(9):915–934CrossRefPubMedGoogle Scholar
  18. 18.
    Smith B. Assessment of dose proportionality. In: Industrial Pharmacokinetics, Eds. Bonate P, Howard D. AAPS Press. 2004Google Scholar
  19. 19.
    Vaccaro SK, Argenti D, Shah BS, Gillen MS, Rohatagi S, Jensen BK. Effect of food and gender on the pharmacokinetics of RP 73401, a phosphodiesterase IV inhibitor. Int J Clin Pharmacol Ther 2000;38(12):588–594PubMedGoogle Scholar
  20. 20.
    Dumas M, d'Athis P, Besancenot JF, Chadoint-Noudeau V, Chalopin JM, Rifle G, Escousse A. Variations of sotalol kinetics in renal insufficiency. Int J Clin Pharmacol Ther Toxicol 1989;27(10):486–489PubMedGoogle Scholar
  21. 21.
    Abdallah H, Jerling M. Effect of hepatic impairment on the multiple-dose pharmacokinetics of ranolazine sustained-release tablets. J Clin Pharmacol 2005;45(7):802–809CrossRefPubMedGoogle Scholar
  22. 22.
    Rohatagi S, Zannikos PN, DePhillips SL, Ferris O, Boutouyrie BX, Jensen BK. Effect of age on the pharmacokinetics (PK) and pharmacodynamics (PD) of a platelet GP IIB/IIIA antagonist, RPR 109891 (Klerval). 13th Annual Meeting of the American Association of Pharmaceutical Scientists, San Francisco. November 1998Google Scholar
  23. 23.
    Shi J, Ludden TM, Melikian AP, Gastonguay MR, Hinderling PH. Population pharmacokinetics and pharmacodynamics of sotalol in pediatric patients with supraventricular or ventricular tachyarrhythmia. J Pharmacokinet Pharmacodyn 2001;28(6):555–575CrossRefPubMedGoogle Scholar
  24. 24.
    AAPS Workshop. Integrated roadmap to biomarkers for drug development method validation and qualification. American Association of Pharmaceutical Scientists, September 8–9, 2005Google Scholar
  25. 25.
    Evens RP, Witcher M. Biotechnology: an introduction to recombinant DNA technology and product availability. Ther Drug Monitoring 1993;15(6):514–520CrossRefGoogle Scholar
  26. 26.
    Carson KL. Flexibility—the guiding principle for antibody manufacturing. Nature Biotechnology 2005;23(9):1054–1058CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Jun Shi
    • 1
  • Vijay O. Bhargava
    • 2
  • Shashank Rohatagi
    • 3
  1. 1.Clinical Pharmacology and Drug DynamicsForest LaboratoriesMO
  2. 2.Metabolism and Pharmacokinetics at Novartis PharmaceuticalNJ
  3. 3.Sankyo PharmaNJ

Personalised recommendations